Presence of unsedimented precipitate in visually non-turbid supernates in the heparin-manganese method for HDL-cholesterol quantitation

Kiss, Zelma H. T.; Simo, I.E.; Ooi, Teik Chye; Meuffels, Mary; Hindmarsh, John

doi:10.1016/s0009-9120(86)80027-3

Cited by 6 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultracentrifugation was utilised to measure LDL‐C values in patients with TG ≥ 4.5 mmol/l. HDL‐C was quantified enzymatically after the removal of apo B‐containing lipoproteins by heparin and manganese chloride precipitation (54,55). Non‐HDL‐C levels were calculated by subtracting HDL‐C from TC values.…”

Section: Methodsmentioning

confidence: 99%

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

Reckless

Henry

Pomykaj

et al. 2008

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

Reckless

Henry

Pomykaj

et al. 2008

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Ultracentri- fugation was utilized to measure LDL-C values in patients with TG ≥4.5 mmol/l. HDL-C was quantified enzymatically after the removal of apo B-containing lipoproteins by heparin and manganese chloride precipitation [23, 24]. Non-HDL-C levels were calculated by subtracting HDL-C from TC values.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event

Brudi

Reckless²,

Henry³

et al. 2008

Cardiology

View full text Add to dashboard Cite

Objective: The aim of the study was to compare the efficacy/safety of doubling the dose of low-, medium- and high-potency statins on lipids/lipoproteins versus ezetimibe/simvastatin (EZE/SIMVA) 10/40 mg in patients with a recent coronary event. Methods: In this open-label study, patients were stratified by baseline statin therapy (low, medium and high potency) and randomized equally to statin dose doubling or EZE/SIMVA 10/40 mg for 12 weeks. Primary analysis concerned change in low-density lipoprotein cholesterol for the whole population. Treatment-by-stratum interaction evaluated the consistency of treatment effect across statin potency strata. Post hoc analysis of between-group efficacy within strata was performed using ANCOVA. Results: Within each stratum, EZE/SIMVA produced significantly greater reductions in low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and non-high-density lipoprotein cholesterol (HDL-C) compared to statin doubling. Numerical trends toward smaller between-group reductions were observed with higher-potency statins and reached statistical significance for apolipoprotein B and non-HDL-C. No significant between-group differences in HDL-C and C-reactive protein were observed within each stratum. EZE/SIMVA produced larger reductions in triglycerides versus low-potency statin, whereas it was similarly effective compared with intermediate-/high-potency statins. The safety/tolerability profiles of the treatments were similar across the strata. Conclusions: EZE/SIMVA 10/40 mg produced greater improvements in lipids with a similar safety profile compared to doubling the dose of low-, medium- and high-potency statins.

show abstract

“…Ultracentrifugation was used to measure LDL-C values in patients with TG N4.5 mmol/L. HDL-C was quantified enzymatically after the removal of Apo B-containing lipoproteins by heparin and manganese chloride precipitation [20,37]. Non-HDL-C levels were calculated by subtracting HDL-C from TC values.…”

Section: Laboratory Methodsmentioning

confidence: 99%

Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease

Vaverková

Farnier²,

Averna

et al. 2011

Clinical Biochemistry

View full text Add to dashboard Cite

show abstract

Presence of unsedimented precipitate in visually non-turbid supernates in the heparin-manganese method for HDL-cholesterol quantitation

Cited by 6 publications

References 5 publications

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event

Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease

Contact Info

Product

Resources

About